CONCORDBIO

- Concord Biotech Limited has approved the allotment of 10,46,16,204 fully paid-up bonus equity shares. - Bonus shares are allotted in the ratio of 1:1 (1 bonus equity share for every 1 existing fully paid-up equity share). - The record date for the bonus issue was Wednesday, November 04, 2026. - Consequent to this allotment, the paid-up share capital of the company increased to ₹20,92,32,408 divided into 20,92,32,408 equity shares of ₹1 each.

Current scenario - Q2 FY27 revenue grew 25% YoY; H1 FY27 revenue grew 26% YoY. - Broad-based growth across all product categories (immunosuppressants, anti-infectives, antifungal, and oncology) and geographies. - Gross margins contracted by ~400 bps YoY due to higher raw material prices (solvents) and product mix, but EBITDA margin remained resilient at 33.8% in Q2 FY27. Changes in trends - API revenue grew 30% YoY, while formulation revenue increased 6% due to changes in customer procurement strategies shifting towards API. - Domestic formulation business showed strong growth of 29% in Q2. Management Guidance & Outlook - Expect to recover full-year margins through revenue improvement, cost optimization, and inventory management. - EBITDA margins expected to move towards historical levels of 38%-40% as new growth drivers scale up. - Maintained zero-debt status with cash and cash equivalents of ~Rs. 445 crores. Capex - Maintenance CapEx guided at Rs. 20-30 crore annually, with total CapEx expected around Rs. 50-60 crore per year (Rs. 100-120 crores total for FY27 and next year). Growth Drivers - Expansion in fermentation-based APIs, CDMO opportunities, and scaling up of the U.S. formulation business via Stellon Biotech. - Launch of the 'Inspira' dermatology division targeting a large domestic market opportunity.

- Concord Biotech conducted its Earnings Call on October 28, 2026, for Q2 and H1 FY27 financial results. - Audio recording of the conference call has been made available on the company's website.

Concord Biotech Limited has informed the stock exchanges about a scheduled Non-Deal Roadshow with analysts and institutional investors. - Concall Date: 3rd & 4th November 2026 - Organised By: UBS - Nature of Meeting: In Person - Place: Singapore

- Q2 FY27 Consolidated Revenue increased 25% YoY to ₹309.1 Cr. - PAT rose 10% YoY to ₹69.6 Cr; EBITDA grew 18% to ₹104.4 Cr. - Board approved issuance of bonus shares in the ratio of 1:1. - Launched new dermatology division 'Inspira' and received 2 ANDA approvals. - Completed USFDA inspection at Unit II facility.

- Concord Biotech Limited has fixed November 04, 2026, as the record date for the issuance of bonus equity shares. - Bonus shares will be issued in the ratio of 1:1 (one bonus equity share for every one existing fully paid-up share). - Thursday, November 05, 2026, shall be the deemed date of allotment of bonus equity shares.

Q2 FY27 Consolidated Revenue ₹309.07Cr vs ₹247.06Cr (▲25.1% YoY) EBITDA ₹103.72Cr vs ₹90.78Cr (▲14.3% YoY) PAT ₹69.57Cr vs ₹63.06Cr (▲10.3% YoY) EBITDA Margin 33.56% vs 36.74% (▼318bps) Board fixed November 04, 2026 as the Record Date for 1:1 Bonus Equity Share issue.

Concord Biotech Limited announced voting results and Scrutinizer's Report of the Postal Ballot dated September 23, 2026. - Both ordinary resolutions were successfully passed with the requisite majority on October 24, 2026. - Resolution 1: Approval for increase in authorized share capital and consequential alteration of the Memorandum of Association passed with 99.98% votes in favour. - Resolution 2: Issuance of Bonus Equity Shares passed with 98.13% votes in favour.

Concall Schedule Concall Date: October 28, 2026 Concall Time: 03:30 PM, IST

- Trading window closed from October 01, 2026 for declaration of Q2 and half-year ended September 30, 2026 results. - Window to re-open 48 hours after the declaration of financial results. - Applies to all Designated Persons and their immediate relatives.

- Concord Biotech Limited has issued a Postal Ballot Notice dated September 23, 2026, seeking shareholders' approval for key corporate actions. - Proposal to increase the Authorised Share Capital from ₹11 crore to ₹22 crore and consequential alteration of the Memorandum of Association. - Proposal for the issuance of bonus equity shares in the ratio of 1:1 (1 bonus share for every 1 existing equity share) by capitalising ₹10.46 crore from the securities premium account. - Remote e-voting period commences on September 25, 2026, and ends on October 24, 2026, with the cut-off date fixed as September 18, 2026.

- Board of Directors approved a 1:1 bonus share issue (1 bonus share for every 1 existing share) by capitalizing the share premium account, subject to shareholder approval. - The company's Authorised Share Capital will be increased from ₹11 Crores to ₹22 Crores, also subject to shareholder approval. - Bonus shares are estimated to be credited/dispatched by November 22, 2026.

- USFDA inspection at Valthera Formulation Facility completed on September 18, 2026. - Received one minor procedural observation, not related to GMP. - No material impact expected on business operations or supplies.

- Investor Meeting Schedule - Meeting Date: 23rd September 2026 - Meeting Time: 12:30 pm - Organized by: JP Morgan Healthcare Trip - Place: Ahmedabad

- Concall Schedule - Concall Date: 26th August 2026 - Concall Time: 01:00 PM to 03:00 PM (IST)

- Q1 FY27 revenue grew by 26.2% YoY to INR257 crores. - EBITDA increased by 34% YoY to INR82 crores, with margins at 32% (▲190 bps YoY). - PAT grew by 31% YoY to INR58 crores, with margins at 22.4% (▲80 bps YoY). - Management aims for INR3,000 crores total revenue in 5-6 years, leveraging existing API and formulation capacities (INR2,200 Cr from API, INR600-700 Cr from formulation). - Injectable facility is commercialized, currently at 5% utilization, with sales to emerging markets expected to start next year; H2 FY27 to focus on domestic contract manufacturing. - EBITDA margins are projected to improve, targeting 40% by FY28 with full ramp-up of new businesses (injectable, Stellon).

- Earnings Call for Q1 FY27 (Quarter ended June 30, 2026) was conducted on August 03, 2026. - The audio recording of the conference call is now available on the company's website.

- Consolidated Revenue ₹257 Cr vs ₹204 Cr (▲26.2% YoY) - EBITDA ₹82 Cr vs ₹61 Cr (▲34.2% YoY) - PAT ₹58 Cr vs ₹44 Cr (▲31.0% YoY) - EBITDA Margin 32.0% vs 30.1% (▲190bps)

- Concord Biotech Limited held its 41st Annual General Meeting (AGM) on July 31, 2026. - All six resolutions, including the adoption of financial statements, declaration of dividend, director appointments, and approval of enhanced limits for inter-corporate loans/guarantees, were passed with requisite majority.

- The 41st Annual General Meeting (AGM) of Concord Biotech Limited was held on July 31, 2026, via Video Conferencing. - The Chairman presented on FY26 operations, financial performance, and future prospects. - Statutory and Secretarial Audit Reports had no qualifications or adverse remarks. - Voting results will be declared within two working days.

- Consolidated Revenue ₹257.49 Cr vs ₹203.99 Cr (▲26.22% YoY) - EBITDA ₹83.65 Cr vs ₹62.89 Cr (▲33.01% YoY) - PAT ₹57.70 Cr vs ₹44.06 Cr (▲30.95% YoY) - EBITDA Margin 32.49% vs 30.83% (▲166bps)

- Concall Schedule - Concall Date: Monday, August 03, 2026 - Concall Time: 3:30 P.M. IST

- 41st Annual General Meeting (AGM) scheduled for Friday, July 31, 2026, at 12:00 Noon. - Record Date for final dividend for FY ended March 31, 2026, is Friday, July 24, 2026. - Book Closure from Saturday, July 25, 2026, to Friday, July 31, 2026. - Dividend payment, if approved, will be by August 30, 2026.

- 41st Annual General Meeting (AGM) on July 31, 2026, via VC/OAVM. The record date for e-voting and dividend is July 24, 2026. - Board recommended a dividend of ₹7.55 per equity share (755%) for FY 2025-26. - Proposed appointment of Mrs. Ekta Gupta as an Independent Director for 5 years. - Proposal to enhance inter-corporate loan/guarantee limits to ₹500 Crores.

- The trading window for equity shares will be closed from July 01, 2026. - It will reopen 48 hours after the Unaudited Financial Results for the quarter ended June 30, 2026, are declared.

- Successful completion of inspection by Pharmacy and Poisons Board (Kenya) and National Drug Authority (Uganda) at Unit-II formulation facility. - The inspection was conducted from June 18, 2026, to June 24, 2026. - This reinforces the company's commitment to quality and strengthens its global manufacturing and regulatory footprint.

- Concord Biotech Limited to acquire 27.38% equity share capital in M/s FSGE Renewable Power Private Limited for ₹6.3 Crores. - FSGE is setting up a Hybrid Wind Solar Power Project (6.3 MW AC Wind & 6.3 MWp DC Solar) in Gujarat for Concord Biotech's Limbasi Facility. - The investment aligns with the company's sustainability commitment, aims to reduce its carbon footprint, and offers long-term financial benefits through energy cost reduction.

- Investor Meetings Scheduled - Date: 24th & 25th June 2026 - Time: 10:00 am onwards - Organized by: Kotak Institutional Equities - Nature: 1x1 / Group Meeting in Mumbai

- Schedule of Analyst / Institutional Investor meetings - Meeting Date: 17th June 2026 - Meeting Time: 10:30 am onwards - Mode: Virtual

- Concord Biotech Limited announced the successful completion of an ANVISA inspection by the Brazilian Health Regulatory Agency at its Limbasi API Manufacturing Facility, conducted from June 8-12, 2026. This strengthens regulatory compliance and supports international expansion into key pharmaceutical markets.

- Concord Biotech received USFDA approval for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets, 5 mg and 10 mg. - Tofacitinib Tablets are indicated for the treatment of various adult and juvenile autoimmune conditions. - The U.S. market for Tofacitinib Tablets is estimated at approximately US$ 500 million. - This approval is expected to enhance the company's product offerings and support long-term growth.